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Abstract: Proton-pump inhibitors (PPIs) are the drugs of choice for the treatment of 
gastroesophageal reﬂ  ux disease (GERD). Esomeprazole is the latest PPI and was developed as the 
S-isomer of omeprazole as an attempt to improve its pharmacokinetic properties. Esomeprazole 
has been reported to have a somewhat higher potency in acid inhibition than other PPIs. Despite 
some controversy, data from clinical trials and meta-analyses indicate that esomeprazole 40 mg 
od for up to 8 weeks provided higher rates of healing of erosive GERD and a greater proportion 
of patients with sustained resolution of heartburn, than omeprazole 20 mg, lansoprazole 30 mg, 
or pantoprazole 40 mg od. Esomeprazole 20 mg od has also been shown to be more effective in 
maintaining healing of erosive GERD compared with lansoprazole 15 mg od or pantoprazole 
20 mg od. However, it is not clear whether these statistically signiﬁ  cant differences are of major 
clinical importance. Esomeprazole 20 mg od is superior to placebo for treatment of non-erosive 
reﬂ  ux disease (NERD) but clinical trials have not shown any signiﬁ  cant differences in efﬁ  cacy 
between esomeprazole 20 mg and omeprazole 20 mg or pantoprazole 20 mg od. Lastly, although 
esomeprazole treatment in GERD has been reported to result in improvement of health-related 
quality of life (QoL) indices, no clinical trials have evaluated the possible differential effects 
of different PPIs on QoL in GERD.
Keywords: esomeprazole, gastro-esophageal reﬂ  ux disease (GERD), esophagitis, proton pump 
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Introduction
Gastro-esophageal reﬂ  ux (GERD) is deﬁ  ned as the reﬂ  ux of gastric contents into the 
esophagus leading to reﬂ  ux symptoms sufﬁ  cient to affect patient well-being and/or 
cause complications (Vakil et al 2006). Population-based studies suggest that heartburn 
is a very common symptom in the general population with a prevalence of 10%–20% 
in the Western world but far from all are consulters. However, in Asia the prevalence 
of GERD-like symptoms is lower and has been reported to be less than 5% (Dent et 
al 2005; Moayyedi and Talley 2006). When traditional endoscopy is used, GERD 
can be subdivided into reﬂ  ux esophagitis (or erosive GERD) and endoscopy-negative 
reﬂ  ux disease (or non-erosive reﬂ  ux disease, NERD) (Moayyedi and Talley 2006; 
Vakil et al 2006). About 50% of patients with the disease have a normal endoscopy 
in referral centers (Johansson et al 1986; Johnsson et al 1987), but in primary care 
the occurrence of esophagitis is lower (Vakil et al 2006). Erosive GERD has been 
associated with complications such as esophageal strictures and Barrett’s esophagus 
(Vakil et al 2006). 
The proton pump inhibitors (PPIs) are substituted benzimidazoles administered as 
enteric-coated tablets or capsules that pass through the stomach and are absorbed in 
the duodenum. They act on the proton pump molecule on the luminal surface of gastric 
parietal cells, resulting in inhibition of acid secretion (Hatlebakk 2003). Esomeprazole 
is the latest PPI and was developed as the S-isomer of omeprazole as an improvement Therapeutics and Clinical Risk Management 2007:3(4) 654
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in its pharmacokinetic properties (Hatlebakk 2003; Kendall 
2003). PPIs are the drugs of choice in the treatment of GERD 
(Moayyedi and Talley 2006).
Esomeprazole is considered to have a somewhat higher 
potency in acid inhibition than other PPIs (Hatlebakk 2003; 
Kendall 2003; Hellstrom and Vitols 2004). However, 
previous reports have reported variable results in comparing 
its efﬁ  cacy in healing erosive GERD, in maintenance therapy 
of healed erosive GERD, and in therapy of NERD compared 
with other PPIs. Some systematic reviews and meta-analyses 
have been published on the efﬁ  cacy of esomeprazole in 
the therapy of erosive GERD (Klok et al 2003; Vakil and 
Fennerty 2003; Edwards et al 2006; Gralnek et al 2006). 
The aim of the current systematic review was to provide an 
update on the efﬁ  cacy of esomeprazole in acid suppression, 
in the acute and maintenance therapy of erosive GERD and 
NERD as well as in improving health-related quality of life 
(QoL) in GERD. Comparison with other PPIs in this context 
was also undertaken.
Data selection
We performed a structured electronic search of PuBMed to 
identify English-language, randomized clinical trials from 
2000 to 2006 comparing esomeprazole vs alternative PPIs 
in the treatment of GERD. The bibliography of systematic 
reviews and meta-analyses performed comparing the efﬁ  cacy 
of esomeprazole vs other PPIs in GERD was searched 
manually for references not found by the strategy described 
above. Abstracts from presentations at conferences, animal 
studies, or data from the manufacturers not published as full-
text articles were not included. A review of the literature on 
esomeprazole and Barrett’s esophagus or extraesophageal 
manifestations of GERD was beyond the scope of this 
article.
Acid suppression
Although investigators agree that GERD is associated with 
dysmotility and results from an imbalance between normal 
defensive factors such as esophageal clearance, lower 
esophageal sphincter tone, and aggressive factors such as acid 
and pepsin, it has become increasingly clear that the key to 
controlling symptoms and to healing esophagitis is decreasing 
the duration of exposure to the acidic reﬂ  uxate (Hunt 1999). 
The duration of esophageal exposure to a reﬂ  uxate with a 
pH of 4.0 or less has been shown to be correlated to mucosal 
injury and to a reduced ability of the injured mucosa to 
proliferate and heal (Bell et al 1992; Hunt 1999). Controlling 
GERD symptoms and healing erosive GERD can be best 
achieved by increasing the gastric pH to 4.0 or above for 
as long a duration as possible (Bell et al 1992; Hunt 1999). 
Furthermore, it has been suggested that in patients with more 
severe grades of esophagitis, there are abnormally high levels 
of nocturnal acid exposure (Bell et al 1992). Also, ulcerative 
esophagitis, esophageal strictures, and Barrett’s esophagus are 
characterized by high levels of supine nocturnal percentage 
acid reﬂ  ux time (Frazzoni et al 2003), indicating that control 
of nocturnal acid secretion is important.
PPIs reduce gastric acid secretion by inhibiting activity of 
the gastric H+/K+-ATPase. They are protonated in the acidic 
gastric environment to active forms, which irreversibly bind 
to the H+/K+-ATPase and inactivate it (Hunt 1999; Hatlebakk 
2003; Hellstrom and Vitols 2004). As PPIs block the last step 
in the pathway to gastric acid secretion, they are effective 
in both basal and stimulated acid secretion (Hunt 1999; 
Hellstrom and Vitols 2004).
The effects of esomeprazole on gastric 
acidity
Recently, acid control with esomeprazole has been compared 
with that of other PPIs in several cross-over studies in either 
patients with GERD or in healthy individuals. As shown 
in Table 1, all studies showed that esomeprazole 40 mg 
od was more effective in maintaining intragastric pH at 4.0 
or lower compared with all other PPIs given at standard 
doses. The same studies demonstrated that esomeprazole 
40 mg od is superior to all other PPIs at standard doses in 
terms of achieving higher 24-hour median intragastric pH 
and in terms of the number of patients achieving intragastric 
pH 4.0 for at least 12 hours per day. Nocturnal pH was 
measured in one of these studies, comparing esomeprazole 
40 mg with pantoprazole 40 mg bd (Miehlke et al 2005). 
During night-time the proportion of time with intragastric 
pH 4.0 was 85.4% with esomeprazole and 63.6% with 
pantoprazole (p = 0.0001). Nocturnal acid breakthrough, 
deﬁ  ned as intragastric pH 4.0 for at least one consecu-
tive hour between 10 pm and 6 am, was observed in 26.7% 
of subjects receiving esomeprazole and in 73.3% of those 
receiving pantoprazole (p = 0.009) (Miehlke et al 2005). Data 
on the effect of esomeprazole on nocturnal pH in comparison 
with other PPIs are otherwise largely lacking.
In certain situations, it is reasonable to use higher than 
approved doses of PPIs, often divided in two doses. These 
include a diagnostic trial for noncardiac chest pain, empiric 
treatment trial for supraesophageal symptoms of GERD, 
cases of partial response to standard dose therapy, cases 
with breakthrough symptoms, GERD patients with severe Therapeutics and Clinical Risk Management 2007:3(4) 655
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esophageal dysmotility, and Barrett’s esophagus (DeVault 
and Castell 2005). A recent double-blind, randomized, cross-
over study investigated the 24-hour intragastric pH proﬁ  le 
of esomeprazole 40 mg bd vs 20 mg bd vs 40 mg od in 25 
healthy volunteers (Katz et al 2004). Esomeprazole 40 mg 
bd provided a mean time of 19.2 hours with intragastric 
pH 4.0 (80.1% of a 24-hour time period, 95% conﬁ  dence 
interval (CI) 74.5%–85.7%) vs 14.2 hours with 40 mg 
od (59.2%, 95% CI 53.7%–64.7%) and 17.5 hours with 
20 mg bd (73.0%, 95% CI 67.4%–78.5%). The percentage 
of time of a 24-hour period that pH remained 4.0 was 
significantly higher with the esomeprazole bd dosing 
regimens compared to the 40 mh od regimen during the 
supine (sleeping) portion of the monitoring period (83.7% 
(95% CI 74.9%–92.4%) for esomeprazole 40 mg bd vs 
79.2% (95% CI 70.5%–87.9%) for esomeprazole 20 mg 
bd vs 57.9% (95% CI 49.0%–66.9%) for esomeprazole 
40 mg od (Katz et al 2004). Esomeprazole 40 mg bd has 
also been shown to be superior to pantoprazole 40 mg bd 
and lansoprazole 30 mg bd in maintaining intragastric pH at 
4.0 or lower (Table 1). These data indicate that twice-daily 
dosing of omeprazole provides signiﬁ  cantly greater acid 
suppression than once-daily dosing and may, therefore, be 
a reasonable consideration for patients requiring greater 
acid-suppression for GERD.
The effects of esomeprazole 
on esophageal acidity
Two studies have assessed the effect of esomeprazole 
on intraesophageal pH proﬁ  les compared to other PPIs. 
Table 1 Gastric acidity, expressed as the percentage of time with intragastric pH >4.0 on day 5 in individuals treated with 
esomeprazole, omeprazole, pantoprazole, and rabeprazole in cross-over randomized pharmacodynamic studies
Reference  Study design  Patient/individual  PPIs compared  Number of  Percentage of time with 
    selection    individuals  intragastric pH >4.0
Lind et al 2000   Double-blind,   GERD symptoms  Eso40 vs eso20  38  69.8% vs 53.0 vs
  randomized,     vs ome 20 od    43.7% p < 0.01
 cross-over
Rohss et al 2002  Open-label,   GERD symptoms  Eso40 vs ome 40 od  130  68.4% vs 62.0%, p < 0.001
 randomized,           
 cross-ove
Wilder-Smith  Open-label,   Healthy volunteers  Eso40 vs lan30 od  24  65% vs 53%, p < 0.001
et al 2003  randomized,
 cross-over
Wilder-Smith  Open-label,  Healthy volunteers  Eso40 vs rabe20 od  23  61% vs 45.1%, p = 0.005
et al 2003  randomized,
 cross-over
Miner et al 2003  Open-label,   GERD symptoms  Eso40 vs lan30 vs   34  58.4% vs 47% vs 49.1
  randomized,     ome20 vs panto40 vs    vs 50.5%, p < 0.001
 cross-over    rabe20  od
Rohss et al 2004  Open-label,   GERD symptoms  Eso40 vs lan30 od  36  57.5% vs 44.6%, p < 0.0001
 randomized
 cross-over 
Rohss et al 2004  Open-label,   GERD symptoms  Eso40 vs ome20 od  38  70% vs 43.8%, p < 0.0001
 randomized,           
 cross-over
Rohss et al 2004  Open-label,   GERD symptoms  Eso40 vs panto40 od  32  67.1% vs 45%, p < 0.001
 randomized,           
 cross-over       
Rohss et al 2004  Open-label,   GERD symptoms  Eso40 vs rabe20 od  35  59.6% vs 44.6%, p < 0.0001
 randomized,         
 cross-over       
Miehlke et al  Single-blind,   Healthy volunteers  Eso40 vs panto bd  30  85.4% vs 63.6%, p = 0.0001
2005 randomized,
 cross-over
Johnson et al  Open-label,   GERD symptoms  Eso40 bd vs lan30  45  81.3% vs 65.4% vs 60.1%
2005  randomized,     bd vs eso40 od     vs 51.3% p < 0.05
  cross-over    vs lan30 od
Abbreviations: Eso, esomeprazole;  GERD, gastroesophageal reﬂ  ux disease; lan, lansoprazole; ome, omeprazole; PPI, proton-pump inhibitor; panto, pantoprazole; rabe, 
rabeprazole.Therapeutics and Clinical Risk Management 2007:3(4) 656
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In a double-blind, randomized, cross-over study in 35 
patients with GERD symptoms, esomeprazole 40 mg 
od was compared with pantoprazole 40 mg od as to 
their effects on intraesophageal pH (Simon et al 2003). 
At baseline the median percentage of total time with 
pH <4.0 was 20.1% in the esomeprazole and 21.3% 
in the pantoprazole group. After 7 days of repeated 
administration, this time was reduced to 0.9% and 2.6% 
respectively, and the mean within-subject differences in 
mean 24-hour pH values between pre- and post-treatment 
values were 19.2% and 18.7% respectively. The Hodges-
Lehmann estimate for the mean within-subjects differences 
in mean 24-hour pH between pre- and post-treatment values 
for the two PPIs was 2.86% and the corresponding 90% 
CI was within the equivalence range set at ± 10% (90% 
CI −2.27; 7.07) (Simon et al 2003). In another open-label 
randomized study, esomeprazole 40 mg od was compared 
with lansoprazole 30 mg od in 30 patients with complicated 
GERD (Frazzoni et al 2006). Normalization of total and 
supine nocturnal esophageal acid exposure was achieved 
in 75% vs 28% (p = 0.026) and 93% vs 50% (p = 0.012) of 
patients in the esomeprazole and the lansoprazole group, 
respectively (Frazzoni et al 2006).
Erosive GERD
Randomized trials evaluating the role of esomeprazole in 
healing of erosive GERD or maintenance therapy of healed 
erosive GERD were reviewed.
Healing of erosive GERD
Several clinical trials have compared esomeprazole with 
other PPIs in healing of erosive GERD (Table 2). Studies 
reported in Table 2 had a similar double-blind, randomized 
design; they included intention-to-treat analyses of healing 
rates, and, as a secondary endpoint, evaluation of therapy 
effect on GERD symptoms. Also, all studies included patients 
who had endoscopy-conﬁ  rmed erosive GERD at baseline. 
Follow-up endoscopy was performed at 4 weeks and at 8 
weeks, except for one study in which patients underwent ﬁ  rst 
follow-up endoscopy at 4 or 6 weeks and second follow-up 
endoscopy at 8 or 10 weeks (Gillessen et al 2004). Although 
at least two randomized studies comparing esomeprazole 
with each of the other PPIs were identiﬁ  ed, no comparative 
studies of esomeprazole vs rabeprazole in erosive GERD 
could be found.
Five out of 8 studies showed that esomeprazole 40 mg 
od achieves better healing rates of erosive esophagitis after 4 
and 8 weeks of treatment compared with omeprazole 20 mg, 
lansoprazole 30 mg, or pantoprazole 40 mg od (Table 1). 
In these trials a total of 13,797 patients with erosive GERD 
were included. The greater efﬁ  cacy of esomeprazole over 
omeprazole, lansoprazole, or pantoprazole was consistent 
when adjusted for baseline severity of esophagitis according 
to the Los-Angeles classification. Furthermore, all of 
these studies showed that esomeprazole 40 mg od is more 
effective than omeprazole 20 mg, lansoprazole 30 mg, or 
pantoprazole 40 mg od in providing resolution of GERD-
associated symptoms (Kahrilas et al 2000; Richter et al 
2001; Castell et al 2002; Fennerty et al 2005; Labenz et al 
2005b). Interestingly, all these studies were supported by the 
manufacturer of esomeprazole.
However, 3/8 comparative studies, in which a total of 
1659 patients were included, showed that there were no sta-
tistically signiﬁ  cant differences in 4- or 8-week healing rates 
between esomeprazole 40 mg od and omeprazole 20 mg, 
lansoprazole 30 mg, or pantoprazole 40 mg od. One of these 
studies showed that healing rates with esomeprazole were 
signiﬁ  cantly higher than those with omeprazole at weeks 
4 (60.8% vs 47.9%, p = 0.02) and 8 (88.4% vs 77.5%, p 
= 0.007) in patients with moderate to severe (Los Angeles 
grade C or D) erosive esophagitis at baseline but were not 
signiﬁ  cantly different for patients with mild (Los Angeles 
grade A or B) erosive esophagitis (Schmitt et al 2006). 
These studies reported similar efﬁ  cacy of esomeprazole 
compared to omeprazole, lansoprazole, or pantoprazole in 
GERD-related symptoms (Howden et al 2002; Gillessen 
et al 2004; Schmitt et al 2006). One out of three of these 
studies was supported by the manufacturer of esomeprazole, 
showing some beneﬁ  ts of esomeprazole for patients with 
more severe esophagitis (Schmitt et al 2006). The other 
two were supported by the manufacturers of lansoprazole, 
showing no difference between lansoprazole and esome-
prazole (Howden et al 2002), and by the manufacturer of 
pantoprazole, showing no difference between pantoprazole 
and esomeprazole (Gillessen et al 2004). Equivalence of 
esomeprazole 40 mg and pantoprazole 40 mg od in treating 
GERD-related symptoms in patients with erosive GERD 
was also reported in a double-blind randomized study in 
which 217 patients with esophagitis were included (Schol-
ten et al 2003). In this trial no follow-up endoscopic evalu-
ation was performed and, thus, no data on healing rates 
could be calculated (Scholten et al 2003).
Helicobacter pylori infection has been shown to elevate 
the intragastric pH achieved by PPIs (Verdu et al 1995; 
Labenz et al 1996). In a study with pantoprazole, it has 
also been proposed that this increased efﬁ  cacy of PPIs in Therapeutics and Clinical Risk Management 2007:3(4) 657
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H. pylori-infected patients may be associated with improved 
symptom control and more rapid healing of the esophagitis 
(Holtmann et al 1999). Furthermore, H. pylori eradication has 
been reported to be a predictor of failure in the treatment of 
GERD with omeprazole 20 mg od (Wu et al 2004) but this 
ﬁ  nding was not reproduced in another study (Kuipers et al 
2004). A recent review on this topic concluded that at present 
it is unclear whether H. pylori should be eradicated in GERD 
patients (Delaney and McColl 2005). In all of the studies 
reviewed here H. pylori status was evaluated in the patients 
included. A signiﬁ  cant effect of H. pylori infection was 
shown in one of the studies comparing esomeprazole 40 mg 
with pantoprazole 40 mg od with H. pylori-negative patients 
experiencing lower healing rates than in H. pylori-positive 
patients (Labenz et al 2005b). No difference was observed 
in the efﬁ  cacy of esomeprazole between H. pylori-negative 
and H. pylori-positive GERD patients in the studies where 
this was investigated (Kahrilas et al 2000; Richter et al 2001; 
Castell et al 2002; Gillessen, et al 2004; Fennerty et al 2005; 
Labenz et al 2005b; Schmitt et al 2006). However, it should 
be taken into consideration that the effect of H. pylori sta-
tus on healing of erosive esophagitis was only a secondary 
endpoint in these studies.
Five meta-analyses on the effect of different PPIs were 
identiﬁ  ed (Edwards et al 2001, 2006; Klok et al 2003; 
Vakil and Fennerty 2003; Gralnek et al 2006), three of 
which focused on the effect of different PPIs (including 
esomeprazole) in healing erosive esophagitis (Edwards 
et al 2001, 2006; Gralnek, et al 2006). In a recent meta-analysis 
comparing the efﬁ  cacy of PPIs in short-term use (Klok 
et al 2003), two studies evaluating healing rates with 
esomeprazole 40 mg vs omeprazole 20 mg od were included 
(Kahrilas et al 2000; Richter et al 2001). The authors 
concluded that esomeprazole was superior to omeprazole 
(relative risk, 1.18; 95% CI 1.14–1.23) (Klok et al 2003). 
Another meta-analysis comparing the efﬁ  cacy of PPIs in 
the management of GERD and peptic ulcer disease (Vakil 
and Fennerty 2003) included three studies comparing 
esomeprazole 40 mg od with either omeprazole 20 mg od 
(Kahrilas et al 2000; Richter et al 2001) or lansoprazole 
30 mg od (Castell et al 2002). The authors concluded that 
esomeprazole was superior to both the PPIs with which 
it was compared in healing of erosive esophagitis and in 
speed of symptom relief (Vakil and Fennerty 2003). In a 
meta-analysis of the efﬁ  cacy of PPIs in acute treatment 
of reﬂ  ux esophagitis (Edwards et al 2001), three studies 
comparing esomeprazole 40 mg with omeprazole 20 mg od 
were included. Two of these were taken into consideration 
in the current review as well (Kahrilas et al 2000; Richter 
et al 2001) but Edwards et al (2001) also used data on ﬁ  le 
from the manufacturer of esomeprazole. They concluded 
that esomeprazole demonstrated higher healing rates 
Table 2 Randomized trials evaluating the efﬁ  cacy of esomeprazole vs other proton-pump inhibitors in healing erosive GERD
Reference  Study design  Number of   PPIs compared  Healing rates intention-to-treat analysis
    patients    4 weeks  8 weeks
Kahrilas et al 2000  Double-blind,   1960  Eso40 vs eso20 vs  75.9% vs 70.5% vs 64.7%,   94.1% vs 89.9% vs 86.9%, 
  randomized    ome20 od  p < 0.05 for eso40 vs  p < 0.05 for all comparisons
        p = 0.09 for
        eso20 vs ome20
Richter et al 2001  Double-blind,  2425  Eso40 vs ome20 od  81.7% vs 68.7%, p < 0.001  93.7% vs 84.2%, p < 0.001
 randomized
Schmitt et al 2006  Double-blind,   1148  Eso40 vs ome20 od  68.2% vs 66.3%, p = 0.385  87% vs 85.8, p = 0.552
 randomized
Castell et al 2002  Double-blind,  5241  Eso40 vs lan30 od  79.4% vs 75.1%, p < 0.05  92.6% vs 88.8%, p < 0.0001
 randomized
Howden et al 2002  Double-blind,  284  Eso40 vs lan30 od  78.3% vs 77%, p > 0.05  91.4% vs 89.1, p > 0.05
 randomized
Fennerty et al 2005  Double-blind,  1001  Eso40 vs lan30 od  55.8% vs 47.5%, p = 0.005  82.4% vs 77.5%, p = 0.005
 randomized
Gillessen et al 2004  Double-blind,  227  Eso40 vs panto40 od  72% vs 74%, p > 0.05a  92% vs 90%, p > 0.05b
 randomized
Labenz et al 2005b  Double-blind,  3170  Eso40 vs panto40 od  81% vs 74.5%, p < 0.001  92% vs 95.5%, p < 0.001
 randomized
aHealing rates regarding the ﬁ  rst follow-up visit at 4 or 6 weeks in this study
bHealing rates at the second follow-up visit at 8 or 10 weeks in this study
Notes: No randomized studies comparing esomeprazole with rabeprazole for healing erosive GERD were found.
Abbreviations: Eso, esomeprazole; ome, omeprazole; lan, lansoprazole; panto, pantoprazole; PPI, proton-pump inhibitor.Therapeutics and Clinical Risk Management 2007:3(4) 658
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than omeprazole at 4 weeks (relative risk 1.14; 95% CI 
1.10–1.18) and 8 weeks (relative risk 1.08: 95% CI 1.05, 
1.10) (Edwards et al 2001). Another meta-analysis by the 
same investigators comparing esomeprazole with other PPIs 
for the healing of erosive esophagitis (Edwards et al 2006) 
included all the randomized trials summarized in Table 2. 
The authors concluded that esomeprazole demonstrated 
higher healing rates compared with standard dose PPIs at 
4 weeks (relative risk 0.92; 95% CI 0.90,0.94; p < 0.00001) 
and at 8 weeks (relative risk 0.95; 95% CI 0.94.0.97; 
p < 0.00001) (Edwards et al 2006). Lastly, a meta-analysis 
of randomized clinical trials comparing esomeprazole 
with other PPIs in healing erosive esophagitis (Gralnek 
et al 2006), included 7 out of the 8 randomized studies 
summarized in Table 2 (Kahrilas et al 2000; Richter et 
al 2001; Castell et al 2002; Howden et al 2002; Gillessen 
et al 2004; Fennerty et al 2005; Labenz et al 2005b) as 
well as data from the manufacturer of esomeprazole 
included in the product information (esomeprazole vs 
omeprazole 20 mg od) and a study published in abstract 
form (esomeprazole 40 mg vs omeprazole 40 mg od). The 
last two mentioned studies have not been published and 
could therefore potentially create a bias in this context. In 
comparing healing rates of erosive esophagitis at 4 and 8 
weeks, the authors found a 10% (relative risk 1.10; 95% CI 
1.05–1.15) and 5% (relative risk 1.05; 95% CI 1.02–1.08) 
relative increase in the probability of healing, respectively, 
with esomeprazole vs alternative PPIs. Also, the authors 
found that esomeprazole conferred an 8% (relative risk 
1.08; 95% CI 1.05–1.11) relative increase in the probability 
of GERD symptom relief at 4 weeks (Gralnek et al 2006). 
In this meta-analysis, the calculated numbers needed to 
treat (NNT) by Los Angeles grade of erosive esophagitis 
(grades A–D) were 50, 33, 14, and 8 (Gralnek et al 2006). 
This suggests that the beneﬁ  t of esomeprazole might be 
important in more severe erosive disease as indicated by 
the decreasing NNTs with increasing Los Angeles grade 
(Gralnek et al 2006). It is at the present time not entirely 
clear if these statistically significant differences are 
clinically signiﬁ  cant.
Maintenance therapy of healed erosive 
GERD
GERD usually relapses once drug therapy is discontinued, with 
about 80% having erosive GERD relapse after 6–12 months 
(DeVault and Castell 2005; Moayyedi and Talley 2006). Thus, 
many patients with GERD require long-term, possibly life-long, 
PPI therapy (Moayyedi and Talley 2006). However, a recent 
study on discontinuation of PPIs in long-term users found that 
20% of GERD patients were able to discontinue their PPIs 
without development of symptoms (Bjornsson et al 2006).
Two double-blind, randomized studies have shown supe-
riority of esomeprazole 40 mg, 20 mg, or 10 mg od to placebo 
in maintenance therapy of healed erosive GERD (Johnson 
et al 2001; Vakil et al 2001). The primary endpoint of both 
studies was endoscopically maintained healing 6 months after 
inclusion. In one of these, 375 patients with endoscopically 
healed esophagitis were randomized to receive esomeprazole 
40 mg, 20 mg, 10 mg, or placebo od (Vakil et al 2001). After 
6 months, signiﬁ  cantly (p < 0.001) more patients remained 
healed with esomeprazole 40 mg (87.9%), 20 mg (78.7%), 
or 10 mg (54.2%) than with placebo (29.1%) at endoscopy 
(Vakil et al 2001). In the other placebo-controlled study, 318 
patients with endoscopically conﬁ  rmed healing of erosive 
GERD were randomized to receive esomeprazole 40 mg, 
20 mg, 10 mg, or placebo od (Johnson et al 2001). After 6 
months, healing was maintained in 93.6% of patients treated 
with esomeprazole 40 mg, 93.2% treated with esomeprazole 
20 mg, and 57.1% treated with esomeprazole 10 mg; 
p < 0.001 vs 29.1% treated with placebo (Johnson et al 
2001). Both of these studies reported that patients treated 
with esomeprazole had less severe heartburn than those 
treated with placebo. However, symptom maintenance data 
from these studies should be interpreted with caution as only 
those patients who maintained healing at the previous visit 
continued to the subsequent visits during the 6-month study 
period (Johnson et al 2001; Vakil et al 2001).
Three clinical trials have compared esomeprazole with 
other PPIs as a maintenance therapy in GERD patients 
with healed erosive esophagitis (Table 3). Studies reported 
in Table 3 had a similar double-blind, randomized design 
and they included intention-to-treat analyses of endoscopy 
and symptom maintenance rates. Also, all three studies 
included patients who had endoscopy-conﬁ  rmed healing of 
their erosive GERD at baseline and follow-up endoscopy 
was performed at 3 and 6 months. The primary endpoint 
was endoscopic and symptom maintenance at 6 months. 
Secondary endpoints were separate endoscopic and symptom 
maintenance rates at 6 months (Lauritsen et al 2003; Labenz 
et al 2005a; Devault et al 2006). No comparative studies of 
esomeprazole vs omeprazole or rabeprazole in maintenance 
therapy of healed erosive GERD could be found.
All three studies showed superiority of esomeprazole 
20 mg to lansoprazole 15 mg or pantoprazole 20 mg od in 
the primary endpoint (Table 3). Furthermore, these studies 
showed superiority of esomeprazole 20 mg to lansoprazoleTherapeutics and Clinical Risk Management 2007:3(4) 659
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15 mg (endoscopic maintenance rate: 84% vs 76%, p < 0.0002 
(Lauritsen et al 2003); 84.5% vs 75.9%, p < 0.0001 
(Devault et al 2006) or pantoprazole 20 mg (88.1% vs 
76.6%, p < 0.0001 (Labenz et al 2005a)) od in maintaining 
endoscopic remission at 6 months. As regards maintenance 
of symptomatic remission only, one of these studies reported 
that esomeprazole 20 mg was more effective than lansoprazole 
15 mg od (symptomatic remission maintenance rate: 78% 
vs 71%, p < 0.001 (Lauritsen et al 2003)) and another that 
esomeprazole 20 mg was more effective than pantoprazole 
20 mg od (94.5% vs 90.5%, p < 0.0001 (Labenz et al 2005a)). 
However, the third study could not show any statistically 
signiﬁ  cant difference between esomeprazole and lansoprazole 
15 mg od in maintaining symptomatic remission (76.4% vs 
73%, p > 0.05) (Devault et al 2006). Lastly, studies comparing 
esomeprazole with lansoprazole showed that esomeprazole 
had consistently higher remission maintenance rates when 
patients were stratiﬁ  ed according to initial severity of erosive 
GERD (Lauritsen et al 2003; Devault et al 2006). However, 
the study comparing esomeprazole 20 mg with pantoprazole 
20 mg od reported that although esomeprazole had higher 
remission maintenance remission rates in patients with erosive 
GERD Los Angeles A–C, differences were not signiﬁ  cant in 
patients with Los Angeles D (Labenz et al 2005a).
Although these data indicate superiority of esome-
prazole compared with lansoprazole or pantoprazole in 
maintenance therapy of healed erosive GERD, there is a 
need for new clinical trials comparing esomeprazole with 
omeprazole and rabeprazole before deﬁ  nite conclusions 
can be drawn.
Non-erosive GERD
Patients with NERD may exhibit similar symptom severity 
to those with erosive GERD but as many as half of them 
may have a normal esophageal pH testing demonstrating 
pH values within the normal range of healthy subjects 
(Martinez et al 2003). Although PPIs have been shown to be 
effective in patients with NERD (Lind et al 1997), symptom 
improvement is lower compared with patients with erosive 
GERD (Martinez et al 2003).
Three papers on clinical trials comparing continuous 
esomeprazole with other PPIs as therapy in NERD patients 
were identified. They all had a similar double-blind, 
randomized design, patients had a normal baseline endoscopy, 
intention-to-treat analysis of data was performed, and study 
duration was 4 weeks (Armstrong et al 2004; Fock et al 
2005; Monnikes et al 2005). No study comparing continuous 
esomeprazole with lansoprazole therapy in NERD was 
identiﬁ  ed.
In one of these papers (Armstrong et al 2004), three 
studies were reported comparing A (n = 1282) esomeprazole 
40 mg, esomeprazole 20 mg, or omeprazole 20 mg od; 
B (n = 693) esomeprazole 40 mg or omeprazole 20 mg 
od; and C (n = 670) esomeprazole 20 mg or omeprazole 
20 mg od. Resolution of heartburn at 4 weeks (no heartburn 
symptoms during the last 7 days) was achieved in similar 
proportions of patients in each treatment arm in study 
A (esomeprazole 40 mg, 56.7%; esomeprazole 20 mg, 
60.5%; omeprazole 20 mg, 58.1%), study B (esomeprazole 
40 mg 70.3%; omeprazole 20 mg 67.9%), and study 
C (esomeprazole 20 mg 61.9%; omeprazole 20 mg, 
59.6%). There were no signiﬁ  cant differences between 
treatment groups within each study. Thus, not only were 
esomeprazole and omeprazole treatments comparable but 
also esomeprazole 40 mg and esomeprazole 20 mg od did 
not yield signiﬁ  cantly different results after 4 weeks in 
patients with NERD (Armstrong et al 2004).
Another clinical trial performed in Asian patients 
(n = 127) with NERD compared esomeprazole 20 mg with 
rabeprazole 10 mg od (Fock et al 2005). After 4 weeks of 
treatment the two PPIs were comparable for the primary 
endpoint of the study, ie, the time needed to achieve a 24-hour 
symptom-free interval for heartburn (esomeprazole 20 mg, 
9 days; rabeprazole 10 mg, 8.5 days; p > 0.05) and regurgi-
tation (esomeprazole 20 mg, 7.5 days; rabeprazole 10 mg, 
6 days; p > 0.05). The authors reported that the two therapies 
Table 3 Randomized trials evaluating the efﬁ  cacy of esomeprazole vs other PPIs in combined endoscopic and symptomatic 
maintenance of healed erosive GERD
Reference  Study design  Number of   PPIs compared  Maintenance rates at
   patients    6  months
Lauritsen et al 2003  Double-blind, randomized  1224  Eso20 vs lan15 od  83 % vs 74%, p < 0.0001
Labenz et al 2005a  Double-blind, randomized  2766  Eso20 vs panto20 od  87% vs 74.9%, p < 0.0001
Devault et al 2006  Double-blind, randomized  1026  Eso20 vs lan15 od  84.5% vs 75.9%, p < 0.0007
Notes: No randomized studies comparing esomeprazole with rabeprazole or omeprazole as to healing erosive GERD were found.
Abbreviations: Eso, esomeprazole; lan, lansoprazole; panto, pantoprazole; PPI, proton-pump inhibitor.Therapeutics and Clinical Risk Management 2007:3(4) 660
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were also comparable in terms of patient’s global evaluation, 
with 87.9% of patients on esomeprazole and 96% of patients 
on rabeprazole reporting that symptoms improved (p > 0.05) 
(Fock et al 2005).
A third study comparing esomeprazole 20 mg with 
pantoprazole 20 mg od for the treatment of NERD patients 
(n = 529) reported that the median time to ﬁ  rst symptom 
relief was 2.0 days for both PPIs (Monnikes et al 2005). 
This study was designed to show non-inferiority of the 
pantoprazole group compared with the esomeprazole group 
with a signiﬁ  cance level of 5%. The Hodges-Lehmann 
estimator and the one-sided 95% CI according to Moses 
were calculated. Non-inferiority was concluded if the lower 
boundary of the 95% CI was greater than –2 days, as the 
difference of 2 days was considered clinically signiﬁ  cant. For 
the primary endpoint variable (time to ﬁ  rst symptom relief), 
the one-sided 95% CI was zero (0.00). Considering that the 
non-inferiority margin was set at –2 days, the lower boundary 
of the 95% CI (0.00) was higher. Thus, the authors concluded 
that pantoprazole was as effective as esomeprazole for time 
to ﬁ  rst symptom relief. Similar results were obtained for time 
to sustained symptom relief (Monnikes et al 2005).
Although no trial comparing continuous esomeprazole 
with lansoprazole therapy was identified, in a recently 
published single-blind study esomeprazole 20 mg on 
demand was compared with lansoprazole 15 mg od (Tsai 
et al 2004). Seven hundred and seventy-four patients with 
NERD who achieved complete resolution of heartburn after 
short term (2–4 weeks) treatment with esomeprazole 20 mg 
were randomized to receive either esomeprazole 20 mg on 
demand or lansoprazole 15 mg continuous daily treatment. 
Signiﬁ  cantly more patients were willing to continue taking 
esomeprazole on demand than lansoprazole od after 
6 months (93% vs 88%, p = 0.02). The authors concluded 
that esomeprazole 20 mg on demand was more acceptable 
to NERD patients compared with lansoprazole 15 mg od 
(Tsai et al 2004). However, it should be pointed out that this 
was a single-blind trial (due to its nature) and that it may 
hardly constitute evidence of superiority of esomeprazole to 
lansoprazole in NERD, as the two PPIs were administered in 
different ways. Therefore, results of this study may merely 
reﬂ  ect patient preference for on-demand therapy.
Long-term (6 month) on-demand esomeprazole treatment 
has been reported to be superior to placebo in the therapy 
of patients with NERD as assessed in two double-blind, 
randomized clinical trials in which NERD patients were 
included after achieving complete resolution of heartburn after 
short-term esomeprazole or omeprazole treatment (Talley 
et al 2001, 2002). In one of these, 342 patients with NERD 
were randomized to receive either esomeprazole 20 mg or 
placebo on demand for 6 months (Talley et al 2001). The 
proportion of patients who discontinued treatment due to 
insufﬁ  cient control of heartburn was signiﬁ  cantly higher 
among placebo compared to esomeprazole recipients (51% vs 
14%, p < 0.0001). In the second study, 721 patients were 
randomized to esomeprazole 20 mg, 40 mg, or placebo on 
demand for 6 months (Talley et al 2002). During this period, 
42% of placebo recipients discontinued treatment due to 
unwillingness to continue, compared with 8% and 11% of 
esomeprazole 20 mg and 40 mg recipients, respectively. 
Although a p < 0.0001 was calculated for comparisons 
between either esomeprazole group and placebo, no 
signiﬁ  cant difference was observed between the esomeprazole 
treatment groups (p = 0.15). Thus the authors concluded that 
esomeprazole 20 mg is superior to placebo for on-demand 
treatment of NERD and that a higher esomeprazole dose 
does not confer additional clinical beneﬁ  t. However, it should 
be pointed out that almost 60% (58%) of patients who were 
randomized to placebo were willing to continue treatment 
(Talley et al 2002). These results clearly indicate that not all 
patients who have had resolution of symptoms after 4 weeks 
of PPI therapy will need continuous treatment in the future.
Esomeprazole in the treatment 
of GERD and health-related quality 
of life
There has been increasing interest in evaluating patient-
reported outcomes such as health-related QoL. It is widely 
accepted that patients with GERD experience decrements 
in health-related QoL compared with the general population 
(Revicki et al 1998; Prasad et al 2003; Pace et al 2005), 
similar to those seen in patients with other chronic diseases 
(Kulig et al 2003). Patients with non-erosive GERD, erosive 
GERD, and Barrett’s esophagus have been reported to have 
similar impairment in health-related QoL (Kulig et al 2003). 
Successful treatment of GERD with symptom resolution 
results in improvements in health-related QoL (Revicki et al 
1998; Prasad et al 2003).
In a recent large uncontrolled study assessing the impact 
of GERD on QoL as well as the effect of acute esomeprazole 
treatment on QoL, indices were evaluated (Kulig et al 2003). 
A total of 6215 patients prospectively diagnosed with GERD 
underwent endoscopy and received treatment with esomepra-
zole 20 mg od (patients with NERD) or 40 mg od (erosive 
GERD). Symptoms and health-related QoL were evaluated at 
baseline and after 2 weeks of treatment by means of validated Therapeutics and Clinical Risk Management 2007:3(4) 661
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questionnaires (Kulig et al 2003). At baseline, QoL in GERD 
patients was lower than in the general population but within 
2 weeks, after treatment with esomeprazole, both symptoms 
and QoL improved in all subscales (Kulig et al 2003).
Recently a large randomized study evaluated the long-term 
effect of two maintenance treatment modalities with esome-
prazole in non-erosive and mild erosive GERD (Pace et al 
2005). Altogether, 6017 patients with GERD symptoms (max 
grade I esophagitis according to Savary-Miller’s classiﬁ  cation 
at baseline endoscopy) received acute treatment with esome-
prazole 40 mg od for 4 weeks. If successfully treated, they 
were randomized to either esomeprazole 20 mg od or esome-
prazole 20 mg on demand for 6 months. Health-related QoL 
was measured with validated questionnaires at baseline as 
well as at the start and conclusion of the maintenance period. 
At baseline, GERD patients had profound reductions in QoL 
indices but after acute esomeprazole treatment for 4 weeks all 
QoL dimensions showed statistically signiﬁ  cant (p < 0.0001) 
improvements. A statistically signiﬁ  cant difference in QoL 
scores was registered at the end of the maintenance phase in 
favor of the continuous regimen (Pace et al 2005).
Lastly, a study from Norway assessed the efficacy 
of three treatment regimens in improving health-related 
QoL in patients with GERD symptoms (Hansen et al 
2006). Following a 4-week symptom-control phase 
(esomeprazole 40 mg od), patients were randomized to 
6 months’ esomeprazole 20 mg od continuously (n = 658), 
esomeprazole 20 mg od on-demand (n = 634), or ranitidine 
150 mg bd continuously (n = 610). Health-related QoL was 
assessed by means of validated questionnaires at baseline as 
well as at the start and conclusion of the maintenance period. 
Esomeprazole 40 mg od improved QoL during the acute 
symptom-control phase. At 6 months, both esomeprazole 
regimens were more effective than ranitidine in all 
dimensions of QoL (p < 0.0001). However, esomeprazole 
20 mg od continuously maintained QoL better than 
esomeprazole on demand and was associated with greater 
patient satisfaction (Hansen et al 2006).
Thus, there are data to support that esomeprazole treat-
ment is associated with improvement in health-related QoL 
indices in patients with GERD, at least compared with raniti-
dine. However, double-blind, randomized studies comparing 
the effect of esomeprazole with that of other PPIs on QoL 
indices at GERD treatment are lacking.
Conclusion
In patients with gastroesophageal reﬂ  ux disease, standard 
doses of esomeprazole maintain intragastric pH above 4 
for signiﬁ  cantly longer periods compared with standard 
doses of other PPIs after 5 days of treatment. Despite some 
controversy, data from clinical trials and meta-analyses 
indicate that esomeprazole 40 mg od for up to 8 weeks 
provides higher rates of healing of erosive GERD and a 
greater proportion of patients with sustained resolution of 
heartburn, than omeprazole 20 mg, lansoprazole 30 mg, or 
pantoprazole 40 mg od. Esomeprazole 20 mg od has also 
been shown to be more effective in maintaining healing 
of erosive GERD compared to lansoprazole 15 mg od or 
pantoprazole 20 mg od. However, it is not clear whether 
these statistically signiﬁ  cant differences are of major clinical 
importance. Comparative efﬁ  cacy studies are also lacking 
between esomeprazole and rabeprazole in healing and 
maintenance of healed erosive GERD as well as between 
esomeprazole and omeprazole or rabeprazole in maintenance 
of healed erosive GERD. Esomeprazole 20 mg od is superior 
to placebo for treatment of NERD but clinical trials have 
not shown any signiﬁ  cant differences in efﬁ  cacy between 
esomeprazole 20 mg and omeprazole 20 mg or pantoprazole 
20 mg od in this group of patients. No comparative data 
between esomeprazole and lansoprazole or rabeprazole in 
NERD could be identiﬁ  ed. Lastly, although esomeprazole 
treatment in GERD has been reported to result in improve-
ment of health-related QoL indices, no clinical trials have 
evaluated the possible differential effects of different PPIs 
on QoL in patients treated for GERD.
Abbreviations
GERD, Gastro-esophageal reﬂ  ux disease; NERD, non-erosive 
reﬂ  ux disease; PPIs, proton pump inhibitors; QoL, quality 
of life; CI, conﬁ  dence interval.
References
Armstrong D, Talley NJ, Lauritsen K, et al. 2004. The role of acid 
suppression in patients with endoscopy-negative reflux disease: 
the effect of treatment with esomeprazole or omeprazole. Aliment 
Pharmacol Ther, 20:413–21.
Bell NJ, Burget D, Howden, et al. 1992. Appropriate acid suppression 
for the management of gastro-oesophageal reﬂ  ux disease. Digestion, 
51(Suppl 1):59–67.
Bjornsson E, Abrahamsson H, Simren M, et al. 2006. Discontinuation of 
proton pump inhibitors in patients on long-term therapy: a double-blind, 
placebo-controlled trial. Aliment Pharmacol Ther, 24:945–54.
Castell DO, Kahrilas PJ, Richter JE, et al. 2002. Esomeprazole 40 mg. com-
pared with lansoprazole 30 mg. in the treatment of erosive esophagitis. 
Am J Gastroenterol, 97:575–83.
Delaney B, McColl K. 2005. Review article: Helicobacter pylori and 
gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 
22(Suppl 1):32–40.
Dent J, El-Serag HB, Wallander MA, et al. 2005. Epidemiology of 
gastro-oesophageal reflux disease: a systematic review. Gut, 
54:710–17.Therapeutics and Clinical Risk Management 2007:3(4) 662
Kalaitzakis and Björnsson
DeVault KR, Castell DO. 2005. Updated guidelines for the diagnosis and 
treatment of gastroesophageal reﬂ  ux disease. Am J Gastroenterol, 
100:190–200.
Devault KR, Johanson JF, Johnson DA, et al. 2006. Maintenance of 
healed erosive esophagitis: a randomized six-month comparison of 
esomeprazole twenty milligrams with lansoprazole ﬁ  fteen milligrams. 
Clin Gastroenterol Hepatol, 4:852–9.
Edwards SJ, Lind T, Lundell L. 2001. Systematic review of proton pump 
inhibitors for the acute treatment of reﬂ  ux oesophagitis. Aliment 
Pharmacol Ther, 15:1729–36.
Edwards SJ, Lind T, Lundell L. 2006. Systematic review: proton 
pump inhibitors PPIs. for the healing of reﬂ  ux oesophagitis – a 
comparison of esomeprazole with other PPIs. Aliment Pharmacol 
Ther, 24:743–50.
Fennerty MB, Johanson JF, Hwang C, et al. 2005. Efﬁ  cacy of esomeprazole 
40 mg vs lansoprazole 30 mg for healing moderate to severe erosive 
oesophagitis. Aliment Pharmacol Ther, 21:455–63.
Fock KM, Teo EK, Ang TL, et al. 2005. Rabeprazole vs esomeprazole in 
non-erosive gastro-esophageal reﬂ  ux disease: a randomized, double-
blind study in urban Asia. World J Gastroenterol, 11:3091–8.
Frazzoni M, De Micheli E, Savarino V. 2003. Different patterns of 
oesophageal acid exposure distinguish complicated reﬂ  ux disease from 
either erosive reﬂ  ux oesophagitis or non-erosive reﬂ  ux disease. Aliment 
Pharmacol Ther, 18:1091–8.
Frazzoni M, Manno M, De Micheli E, et al. 2006. Intra-oesophageal 
acid suppression in complicated gastro-oesophageal reﬂ  ux disease: 
esomeprazole versus lansoprazole. Dig Liver Dis, 38:85–90.
Gillessen A, Beil W, Modlin IM, et al. 2004. 40 mg pantoprazole and 40 mg 
esomeprazole are equivalent in the healing of esophageal lesions and 
relief from gastroesophageal reﬂ  ux disease-related symptoms. J Clin 
Gastroenterol, 38:332–40.
Gralnek IM, Dulai GS, Fennerty MB, et al. 2006. Esomeprazole Versus 
Other Proton Pump Inhibitors in Erosive Esophagitis: A Meta-
Analysis of Randomized Clinical Trials. Clin Gastroenterol Hepatol, 
4:1452–8.
Hansen AN, Bergheim R, Fagertun H, et al. 2006. Long-term management 
of patients with symptoms of gastro-oesophageal reﬂ  ux disease – a 
Norwegian randomised prospective study comparing the effects of 
esomeprazole and ranitidine treatment strategies on health-related 
quality of life in a general practitioners setting. Int J Clin Pract, 
60:15–22.
Hatlebakk JG. 2003. Review article: gastric acidity – comparison of esome-
prazole with other proton pump inhibitors. Aliment Pharmacol Ther, 
17(Suppl 1):10–15; discussion 16–17.
Hellstrom PM, Vitols S. 2004. The choice of proton pump inhibitor: does 
it matter? Basic Clin Pharmacol Toxicol, 94:106–11.
Holtmann G, Cain C, Malfertheiner P. 1999. Gastric Helicobacter pylori 
infection accelerates healing of reﬂ  ux esophagitis during treatment 
with the proton pump inhibitor pantoprazole. Gastroenterology, 
117:11–16.
Howden CW, Ballard ED II, Robieson W. 2002. Evidence for therapeutic 
equivalence of lansoprazole 30 mg and esomeprazole in the treatment 
of erosive esophagitis. Clin Drug Investig, 22:99–109.
Hunt RH. 1999. Importance of pH control in the management of GERD. 
Arch Intern Med, 159, 649–57.
Johansson KE, Ask P, Boeryd B, et al. 1986. Oesophagitis, signs of 
reﬂ  ux, and gastric acid secretion in patients with symptoms of gastro-
oesophageal reﬂ  ux disease. Scand J Gastroenterol, 21:837–47.
Johnson DA, Benjamin SB, Vakil NB, et al. 2001. Esomeprazole once 
daily for 6 months is effective therapy for maintaining healed erosive 
esophagitis and for controlling gastroesophageal reﬂ  ux disease symp-
toms: a randomized, double-blind, placebo-controlled study of efﬁ  cacy 
and safety. Am J Gastroenterol, 96:27–34.
Johnson DA, Stacy T, Ryan M, et al. 2005. A comparison of esomeprazole 
and lansoprazole for control of intragastric pH in patients with 
symptoms of gastro-oesophageal reﬂ  ux disease. Aliment Pharmacol 
Ther, 22:129–34.
Johnsson F, Joelsson B, Gudmundsson K, et al. 1987. Symptoms and 
endoscopic ﬁ  ndings in the diagnosis of gastroesophageal reﬂ  ux disease. 
Scand J Gastroenterol, 22:714–18.
Kahrilas PJ, Falk GW, Johnson DA, et al. 2000. Esomeprazole improves 
healing and symptom resolution as compared with omeprazole in reﬂ  ux 
oesophagitis patients: a randomized controlled trial. The Esomeprazole 
Study Investigators. Aliment Pharmacol Ther, 14:1249–58.
Katz PO, Castell DO, Chen Y, et al. 2004. Intragastric acid suppression and 
pharmacokinetics of twice-daily esomeprazole: a randomized, three-
way crossover study. Aliment Pharmacol Ther, 20:399–406.
Kendall MJ. 2003. Review article: Esomeprazole – the ﬁ  rst proton pump 
inhibitor to be developed as an isomer. Aliment Pharmacol Ther, 
17(Suppl 1):1–4.
Klok RM, Postma MJ, van Hout BA, et al. 2003. Meta-analysis: comparing 
the efﬁ  cacy of proton pump inhibitors in short-term use. Aliment 
Pharmacol Ther, 17:1237–45.
Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. 2004. Cure of Helico-
bacter pylori infection in patients with reﬂ  ux oesophagitis treated with 
long term omeprazole reverses gastritis without exacerbation of reﬂ  ux 
disease: results of a randomised controlled trial. Gut, 53:12–20.
Kulig M, Leodolter A, Vieth M, et al. 2003. Quality of life in relation to 
symptoms in patients with gastro-oesophageal reﬂ  ux disease – an 
analysis based on the ProGERD initiative. Aliment Pharmacol Ther, 
18:767–76.
Labenz J, Armstrong D, Lauritsen K, et al. 2005a. Esomeprazole 20 mg 
vs pantoprazole 20 mg for maintenance therapy of healed erosive 
oesophagitis: results from the EXPO study. Aliment Pharmacol Ther, 
22:803–11.
Labenz J, Armstrong D, Lauritsen K, et al. 2005b. A randomized 
comparative study of esomeprazole 40 mg versus pantoprazole 40 mg 
for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol 
Ther, 21:739–46.
Labenz J, Tillenburg B, Peitz U, et al. 1996. Helicobacter pylori augments 
the pH-increasing effect of omeprazole in patients with duodenal ulcer. 
Gastroenterology, 110:725–32.
Lauritsen K, Deviere J, Bigard MA, et al. 2003. Esomeprazole 20 mg 
and lansoprazole 15 mg in maintaining healed reﬂ  ux oesophagitis: 
Metropole study results. Aliment Pharmacol Ther, 17:333–41.
Lind T, Havelund T, Carlsson R, et al. 1997. Heartburn without oesophagitis: 
efﬁ  cacy of omeprazole therapy and features determining therapeutic 
response. Scand J Gastroenterol, 32:974–9.
Lind T, Rydberg L, Kyleback A, et al. 2000. Esomeprazole provides improved 
acid control vs omeprazole In patients with symptoms of gastro-
oesophageal reﬂ  ux disease. Aliment Pharmacol Ther, 14:861–7.
Martinez SD, Malagon IB, Garewal HS, et al. 2003. Non-erosive reﬂ  ux 
disease NERD – acid reﬂ  ux and symptom patterns. Aliment Pharmacol 
Ther, 17:537–45.
Miehlke S, Madisch A, Kirsch C, et al. 2005. Intragastric acidity during 
treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg 
twice daily – a randomized, two-way crossover study. Aliment Phar-
macol Ther, 21:963–7.
Miner P Jr, Katz PO, Chen Y, et al. 2003. Gastric acid control with esome-
prazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a 
ﬁ  ve-way crossover study. Am J Gastroenterol, 98:2616–20.
Moayyedi P, Talley NJ. 2006. Gastro-oesophageal reﬂ  ux disease. Lancet, 
367:2086–100.
Monnikes H, Pfaffenberger B, Gatz G, et al. 2005. Novel measurement of 
rapid treatment success with ReQuest: ﬁ  rst and sustained symptom 
relief as outcome parameters in patients with endoscopy-negative 
GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion, 
71:152–8.
Pace F, Negrini C, Wiklund I, et al. 2005. Quality of life in acute and main-
tenance treatment of non-erosive and mild erosive gastro-oesophageal 
reﬂ  ux disease. Aliment Pharmacol Ther, 22:349–56.
Prasad M, Rentz AM, Revicki DA. 2003. The impact of treatment for 
gastro-oesophageal reﬂ  ux disease on health-related quality of life: a 
literature review. Pharmacoeconomics, 21:769–90.Therapeutics and Clinical Risk Management 2007:3(4) 663
Esomeprazole in GERD
Revicki DA, Wood M, Maton PN, et al. 1998. The impact of gastro-
esophageal reﬂ  ux disease on health-related quality of life. Am J Med, 
104:252–8.
Richter JE, Kahrilas PJ, Johanson J, et al. 2001. Efﬁ  cacy and safety of 
esomeprazole compared with omeprazole in GERD patients with 
erosive esophagitis: a randomized controlled trial. Am J Gastroenterol, 
96:656–65.
Rohss K, Hasselgren G, Hedenstrom H. 2002. Effect of esomeprazole 
40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with 
symptoms of gastroesophageal reﬂ  ux disease. Dig Dis Sci, 47:954–8.
Rohss K, Lind T, Wilder-Smith C. 2004. Esomeprazole 40 mg provides more 
effective intragastric acid control than lansoprazole 30 mg, omepra-
zole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients 
with gastro-oesophageal reﬂ  ux symptoms. Eur J Clin Pharmacol, 
60:531–9.
Schmitt C, Lightdale CJ, Hwang C, et al. 2006. A multicenter, randomized, 
double-blind, 8-week comparative trial of standard doses of esome-
prazole 40 mg. and omeprazole 20 mg. for the treatment of erosive 
esophagitis. Dig Dis Sci, 51:844–50.
Scholten T, Gatz G, Hole U. 2003. Once-daily pantoprazole 40 mg and 
esomeprazole 40 mg have equivalent overall efﬁ  cacy in relieving 
GERD-related symptoms. Aliment Pharmacol Ther, 18:587–94.
Simon B, Muller P, Pascu O, et al. 2003. Intra-oesophageal pH proﬁ  les and 
pharmacokinetics of pantoprazole and esomeprazole: a crossover study 
in patients with gastro-oesophageal reﬂ  ux disease. Eur J Gastroenterol 
Hepatol, 15:791–9.
Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. 2001. Esomeprazole 20 mg 
maintains symptom control in endoscopy-negative gastro-oesophageal 
reﬂ  ux disease: a controlled trial of on-demand therapy for 6 months. 
Aliment Pharmacol Ther, 15:347–54.
Talley NJ, Venables TL, Green JR, et al. 2002. Esomeprazole 40 mg and 
20 mg is efﬁ  cacious in the long-term management of patients with 
endoscopy-negative gastro-oesophageal reﬂ  ux disease: a placebo-
controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol 
Hepatol, 14:857–63.
Tsai HH, Chapman R, Shepherd A, et al. 2004. Esomeprazole 20 mg 
on-demand is more acceptable to patients than continuous lanso-
prazole 15 mg in the long-term maintenance of endoscopy-negative 
gastro-oesophageal reﬂ  ux patients: the COMMAND Study. Aliment 
Pharmacol Ther, 20:657–65.
Vakil N, Fennerty MB. 2003. Direct comparative trials of the efﬁ  cacy 
of proton pump inhibitors in the management of gastro-oesophageal 
reﬂ  ux disease and peptic ulcer disease. Aliment Pharmacol Ther, 
18:559–68.
Vakil NB, Shaker R, Johnson DA, et al. 2001. The new proton pump inhibitor 
esomeprazole is effective as a maintenance therapy in GERD patients 
with healed erosive oesophagitis: a 6-month, randomized, double-blind, 
placebo-controlled study of efﬁ  cacy and safety. Aliment Pharmacol 
Ther, 15:927–35.
Vakil N, van Zanten SV, Kahrilas P, et al. 2006. The Montreal deﬁ  nition 
and classiﬁ  cation of gastroesophageal reﬂ  ux disease: a global evidence-
based consensus. Am J Gastroenterol, 101:1900–20; quiz 1943.
Verdu EF, Armstrong D, Fraser R, et al. 1995. Effect of Helicobacter 
pylori status on intragastric pH during treatment with omeprazole. 
Gut, 36:539–43.
Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, et al. 2003. Esomeprazole 
40 mg provides improved intragastric acid control as compared with 
lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. 
Digestion, 68:184–8.
Wu JC, Chan FK, Ching JY, et al. 2004. Effect of Helicobacter pylori 
eradication on treatment of gastro-oesophageal reﬂ  ux disease: a double 
blind, placebo controlled, randomised trial. Gut, 53:174–9.